Boryung Biopharma Establishes mRNA New Drug Developer Bifijin

Development of Highly Accurate and Effective mRNA Anticancer Agent
Targeting Phase 1 Clinical Approval for mRNA-Based Triple-Negative Breast Cancer Treatment
"Combining Excellent Production Capacity with Subsidiary Technology to Establish Mid- to Long-Term Growth Engine"

[Asia Economy Reporter Lee Gwan-joo] Boryung Biopharma announced on the 8th that it has established 'Bipijin' by acquiring the research division of its investment affiliate, Pobiokorea, to secure mRNA-based technology and expand its pipeline.

Pobiokorea, a biological material development company, has been developing new drugs using proprietary mRNA technology since 2014. Boryung Biopharma invested in Pobiokorea in 2017 to secure research and development (R&D) capabilities and has been promoting the introduction of mRNA drug-based technology.

Bipijin is developing various anti-cancer agents utilizing the mRNA patented substance (T001) based on a technology patent (SV4) that targets cancer cells with more than 900 times higher accuracy than existing known therapeutics and technology that effectively delivers drugs to cancer cells.

Existing anti-cancer agents suppress cancer cell proliferation by blocking nutrients supplied to cancer cells, but they have the disadvantage of being less effective when cancer cells metastasize by developing metabolism in other ways. In contrast, Bipijin possesses technology that fundamentally suppresses cancer cell proliferation by comprehensively regulating metabolism inside cancer cells and has been conducting the project "Development of Triple-Negative Breast Cancer (TNBC) Targeted Anti-Cancer Agents," a small and medium-sized enterprise technology innovation development project since 2020, aiming for clinical phase 1 approval of an "mRNA-based triple-negative breast cancer treatment" within this year.

Additionally, by combining lipid nanoparticle (LNP) technology for mRNA delivery with outer membrane vesicle (OMV) technology, Bipijin and Boryung Biopharma are jointly promoting the development of an mRNA vaccine platform that replaces existing vaccine development methods based on differentiated drug delivery technology capable of effectively delivering various antigens and mRNA drug combinations.

Boryung Biopharma plans to create mid- to long-term growth engines by strengthening R&D through subsidiaries such as Lucas Bio (cell therapy) and Bipijin (mRNA anti-cancer agents and vaccines), which have technological capabilities in next-generation therapeutic development, in addition to its existing national essential vaccine business base, ahead of its initial public offering (IPO) scheduled for December this year.

Lee Young, Head of Management at Boryung Biopharma, said, “The establishment of Bipijin is significant in that we have secured research capabilities in the mRNA vaccine field, which has emerged after COVID-19,” and added, “We plan to further strengthen our competitiveness as a vaccine leader through synergy with Boryung Biopharma’s abundant experience in development and manufacturing.”

This content was produced with the assistance of AI translation services.